Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Candel Therapeutics' new prostate cancer treatment shows significant success in trial, boosting stock 66%.
Candel Therapeutics' CAN-2409 immunotherapy showed significant improvement in disease-free survival when combined with radiation therapy for prostate cancer patients.
The Phase 3 trial met its primary endpoint with no new safety concerns, leading to a 66% rise in the company's stock price.
If approved, this could offer a new effective treatment option for over 100,000 men diagnosed annually in the U.S.
12 Articles
El nuevo tratamiento contra el cáncer de próstata de Candel Therapeutics muestra un éxito significativo en los ensayos, aumentando el stock 66%.